

Deep Remission

Top-Down Treatment Strategies and
Real-World Data in Patients with UC:
An Interactive and Innovative Case Series

Sunday, May 7, 2017

6:00 PM – 6:30 PM Buffet; 6:30 PM – 8:00 PM Presentation
Sheraton Grand, Chicago Ballroom 8-10

www.cmeoutfitters.com/UCcase17

This program is not affiliated with Digestive Disease Week®.

Provided by
CME
Outfitters 

Deep Remission

Top-Down Treatment Strategies and Real-World Data in Patients with UC:
An Interactive and Innovative Case Series



AGENDA

- 6:00 pm** Registration/Dinner
- 6:30 pm** Introductions/Learning Objective Review
- 6:35 pm** Disease Activity vs. Disease Severity: Early Implementation of Biologic Therapy to Optimize Outcomes
- 6:55 pm** Treat-to-Target Strategies: The Ins and Outs of Mucosal Healing
- 7:10 pm** Therapies for UC: Efficacy/Safety Profiles
- 7:20 pm** Real-World Data on the Use of Biologic Therapy for UC: How Does the Data Fit Into Clinical Practice?
- 7:40 pm** Q&A
- 8:00 pm** Conclusion

FACULTY

Maria T. Abreu, MD (Moderator)

Crohn's & Colitis Center, University of Miami Miller School of Medicine
Miami, FL

Arthur A. Kornbluth, MD

Inflammatory Bowel Disease Center, Mount Sinai School of Medicine
New York, NY

Miguel Regueiro, MD, AGAF, FACP, FASCP

University of Pittsburgh Medical Center
Pittsburgh, PA

TARGET AUDIENCE

Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers treating patients with ulcerative colitis (UC).

COMMERCIAL SUPPORT STATEMENT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

SYMPOSIUM DETAILS

For details on this symposium visit www.cmeoutfitters.com/UCcase17 or scan the QR code on the right.



Deep Remission

Top-Down Treatment Strategies and Real-World Data in Patients with UC:
An Interactive and Innovative Case Series



LEARNING OBJECTIVES

- Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
- Apply the unique risk/benefit profiles of different biologic therapies when making treatment decisions based on individual prognosis and severity of disease.
- Utilize data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.

The following learning objectives pertain only to those requesting CNE credit:

- Differentiate between disease activity and disease severity to drive treatment decisions in patients with UC.
- Explain the unique risk/benefit profiles of different biologic therapies for making treatment decisions based on individual prognosis and severity of disease.
- Describe data from real-world studies on the use and effectiveness of biologic therapy for UC to initiate early, effective treatment for patients with UC.

ACCREDITATION STATEMENTS

CME Credit: CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by the Accreditation Council for Continuing Medical Education.

CNE Credit: Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for *AMA PRA Category 1 Credit*[™] through the American Academy of Nurse Practitioners (AANP). AANP will accept *AMA PRA Category 1 Credit*[™] from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit: CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs).

Universal Activity Number: 0376-0000-17-011-L01-P

Type: knowledge-based

#UCcase17

Deep Remission

Top-Down Treatment Strategies and
Real-World Data in Patients with UC:
An Interactive and Innovative Case Series



Maria T. Abreu, MD (Moderator)

Director, Crohn's & Colitis Center
Martin Kalser Chair in Gastroenterology
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami Miller School of Medicine
Miami, FL

Biography

Dr. Abreu received her undergraduate and medical degrees from the University of Miami. Her postdoctoral training included an internship and residency in medicine at the Brigham and Women's Hospital in Boston, Massachusetts. She then completed a fellowship in gastroenterology and a postdoctoral fellowship in molecular and cancer biology at the University of California, Los Angeles. Prior to joining the University of Miami Miller School of Medicine, Dr. Abreu served as director of the Inflammatory Bowel Disease (IBD) Center and associate professor of medicine in the Division of Gastroenterology at the Mount Sinai School of Medicine in New York.

A member of the American Society of Clinical Investigators (ASCI) and one of American's Top Doctors (Castle and Connely), Dr. Abreu has published more than 90 peer-reviewed articles, book chapters, and reviews. She is a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Gastroenterology, as well as a Fellow of the American College of Physicians. Dr. Abreu serves a leading role in several professional societies, including the American College of Gastroenterology's Women's Committee, the AGA Under-represented Minorities Committee, and the National Institutes of Health's Gastrointestinal Mucosal Pathobiology (GMPB) Study Section.

Dr. Abreu's research interest is host-bacterial interactions and, in particular, the role of toll-like receptor signaling in intestinal inflammation. Her translational work has focused on genotype-phenotype relationships in inflammatory bowel disease and prediction of response to medical therapies. She is a frequent speaker at national and international symposia on basic science and clinical topics.

Deep Remission

Top-Down Treatment Strategies and
Real-World Data in Patients with UC:
An Interactive and Innovative Case Series



Arthur A. Kornbluth, MD

Clinical Professor of Medicine
Inflammatory Bowel Disease Center
Henry D. Janowitz Division of Gastroenterology
Mount Sinai School of Medicine
New York, NY

Biography

Dr. Kornbluth received his medical degree from Downstate Medical University in New York and completed his postgraduate training in internal medicine as both resident and Chief Resident at the Albert Einstein College of Medicine in the Bronx. He was a Gastroenterology Fellow at Mount Sinai Hospital Medical Center.

A Diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine, for Internal Medicine and Gastroenterology, Dr. Kornbluth holds membership in the American Gastroenterological Association, American College of Gastroenterology, and the Alpha Omega Alpha Honor Medical Society for which he was selected as both an honored educator and again as an honored clinician. Dr. Kornbluth has trained medical students, residents and Gastroenterology Fellows for over 25 years in clinical gastroenterology. As a medical educator, Dr. Kornbluth has taught and lectured extensively in the United States and internationally, and is the Founder and annual Course Director of the Mt. Sinai IBD Consultants Course for the last 11 years. He has received numerous awards as a medical educator, including the Teacher of the Year for six consecutive years at the Mount Sinai School of Medicine. In 2009, he was awarded the Downstate Medical University Alumni William H. Dock Master Teaching Award.

Dr. Kornbluth has published more than 100 articles, abstracts, and book chapters. He is the principal author of all three editions of the Ulcerative Colitis Practice Guidelines in Adults published by the American College of Gastroenterology. He has also twice been the principal author on the chapter on Crohn's Disease in the *Sleisenger and Fordtran Textbook of Gastroenterology*. He has served as an Associate Editor for the *Inflammatory Bowel Disease Journal* and has published in, and is a reviewer for, many peer-reviewed journals, including *The New England Journal of Medicine*, *Annals of Internal Medicine*, *American Journal of Gastroenterology*, *Clinical Gastroenterology and Hepatology*, *Inflammatory Bowel Disease*, *Journal of Clinical Gastroenterology*, *Alimentary Pharmacology and Therapeutics*, and *Gastroenterology*. Currently, he is an investigator on a number of clinical trials examining new therapeutic agents in inflammatory bowel disease, and most recently he has been analyzing the role of biosimilar drugs in the management of inflammatory bowel disease.

Deep Remission

Top-Down Treatment Strategies and
Real-World Data in Patients with UC:
An Interactive and Innovative Case Series



Deep Remission

Top-Down Treatment Strategies and
Real-World Data in Patients with UC:
An Interactive and Innovative Case Series



Miguel Regueiro, MD, FACP, FACG, AGAF

Professor of Medicine, Professor of Clinical and
Translational Science
University of Pittsburgh School of Medicine
Associate Chief, Education
Division of Gastroenterology, Hepatology, and Nutrition
Clinical Medical Director of Inflammatory Bowel Disease
Senior Medical Lead of Specialty Medical Homes
University of Pittsburgh Medical Center
Pittsburgh, PA

Biography

Dr. Regueiro earned his bachelor's degree at the University of Pennsylvania, his medical degree at Drexel University and completed his internal medicine internship and residency, and clinical and research fellowship training in gastroenterology at Harvard Medical School's Beth Israel Hospital.

Dr. Regueiro is Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine. He is the IBD Clinical Medical Director and Associate Chief for Education and former Director of the Gastroenterology, Hepatology, and Nutrition Fellowship Training Program at the University of Pittsburgh Medical Center. He is also Senior Medical Lead of Specialty Medical Homes at UPMC.

Dr. Regueiro's main clinical and research interest is inflammatory bowel disease (IBD), with a focus on the natural course of these diseases and postoperative prevention of Crohn's disease. Recently, he has been involved in developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Abreu reports she serves on the speaker's bureau for AbbVie Inc.; and Imedex. She is a consultant for Eli Lilly and Company; Focus Medical Communications; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Theravance Biopharma US, Inc.; and UCB, Inc. She serves on the scientific advisory board for AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Roche Pharmaceuticals; and Shire.

Dr. Kornbluth reports that he receives research support from AbbVie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc. He serves on the speakers bureau for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited; Prometheus Laboratories Inc.; and Santarus, Inc./Salix Pharmaceuticals. He serves on the advisory board for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc./Takeda Pharmaceutical Company Limited; and Prometheus Laboratories Inc.

Dr. Regueiro reports that he is a consultant for AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.

Kimberly Murray, RN, MS (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff:
No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

